anti-Nipah_008
| anti-Nipah_ID | anti-Nipah_008 |
| anti-Nipah Drug | N-[4-(1H-Tetrazol-1-yl)phenyl]-3,4-dihydro-2-naphthalenesulfonamide |
| Nipah virus strain | NiV (Malaysia-1999) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | in-vitro |
| Models used to test anti-Nipah activity | Vero |
| Mode of infection to test anti-Nipah activity | Adsorption |
| Viral titer to test anti-Nipah activity | 0.006 MOI |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | NA |
| Duration of Drug delivery for anti-Nipah activity | 72 hours |
| Drug concentration used to test anti-Nipah activity | 3.9 μM |
| Assays used to test anti-Nipah activity | Iluminescence |
| anti-Nipah activity | Decrease [Effective concentration (50 %)] |
| References | Tigabu B, Rasmussen L, White EL, Tower N, Saeed M, Bukreyev A, Rockx B, LeDuc JW, Noah JW A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus. Assay Drug Dev Technol. 2014 Apr;12(3):155-61. doi: 10.1089/adt.2013.567 |
| Comments | A total of 23 compounds were identified with EC50 values ranging from 3.9 to 20.0__M and selectivities >10 against NiV. Three sulfonamide compounds with EC50 values <12__M were further characterized for their point of intervention in the viral replication cycle and for broad antiviral efficacy. |